CurrentCignaPolicy IP0033

Dabigatran

Cigna coverage policy governing prior authorization, medical necessity criteria, preferred product rules, and limitations for dabigatran capsules (Pradaxa/generic) and Pradaxa oral pellets across applicable Cigna lines of business.

Policy Summary

PayerCigna

PolicyDabigatran

Policy CodePolicy IP0033

Change TypeMultiple material revisions (age limits, prior auth removal, preferred product updates)

Effective DateAug 15, 2025

Next Review Date

Key ActionPrior authorization is recommended for prescription benefit coverage of dabigatran capsules; verify plan-specific PA rules because PA was removed for generic dabigatran on Employer and Individual & Family plans.

SourceLink

POLICY UPDATE CHANGES

Age restrictions were added for multiple indications for dabigatran capsules (atrial fibrillation; DVT/PE treatment; DVT/PE recurrence prevention; DVT/PE prophylaxis after hip and knee replacement; other thromboembolic-related conditions).

Pradaxa oral pellets: removed the requirement for 5 days of parenteral anticoagulant therapy for VTE treatment indication.

Employer and Individual & Family Plans preferred product criteria were changed to extend coverage approaches across additional capsule strengths (75 mg, 110 mg, 150 mg) and clarified swallowing/difficulty options for oral pellets.

Conditions Not Covered: prophylaxis of VTE in individuals with Factor V Leiden thrombophilia and antiphospholipid was removed.

Prior authorization requirements for generic dabigatran capsules were removed on Employer and Individual & Family plans.

IP0033Coverage Policy Number

2025-08-15Effective date

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

inv-01: Initial therapy - Pradaxa capsules

Pradaxa capsules are considered medically necessary when ALL of the following are met (1 and 2):

Overall requirement: (1) Diagnosis of ONE of the listed indications AND (2) Preferred product criteria is met

Approvals provided for specified durations

Diagnosis (choose one): Atrial fibrillation (or atrial flutter) — Approve for 1 year if patient is ≥ 18 years of age

from FDA-approved indications

DVT/PE treatment: Deep Vein Thrombosis or Pulmonary Embolism, Treatment — Approve for 1 year if patient is ≥ 8 years of age

from FDA-approved indications

DVT/PE to reduce risk of recurrence: Deep Vein Thrombosis or Pulmonary Embolism, To Reduce the Risk of Recurrence — Approve for 1 year if patient is ≥ 8 years of age

from FDA-approved indications

DVT/PE prophylaxis after hip replacement: Deep Vein Thrombosis or Pulmonary Embolism in a Patient Undergoing Hip Replacement Surgery, Prophylaxis — Approve for 60 days if patient is ≥ 18 years of age

from FDA-approved indications

DVT prophylaxis after knee replacement: Deep Vein Thrombosis in a Patient Undergoing Knee Replacement Surgery, Prophylaxis — Approve for 60 days if patient is ≥ 18 years of age

other use with supportive evidence

Treatment or prevention of other thromboembolic-related conditions: Approve for 6 months if patient meets both of the following (i and ii)

Examples include superficial vein thrombosis, splanchnic vein thrombosis, hepatic vein thrombosis, or prophylaxis in a high-risk patient

Other conditions detail (i): Patient is ≥ 8 years of age

chunk 9

Other conditions detail (ii) - choose one: a. Patient has had failure, contraindication, or intolerance to warfarin, fondaparinux, or a low molecular weight heparin product (e.g., enoxaparin, dalteparin) OR b. Patient has been started on dabigatran capsules for the treatment of an acute thromboembolic condition

Patients who have tried apixaban, apixaban sprinkle, rivaroxaban (tablets or suspension), or edoxaban are not required to try warfarin/fondaparinux/LMWH

inv-02: Initial therapy - Pradaxa oral pellets (pediatric)

Pradaxa oral pellets are considered medically necessary when ALL of the following are met (1 and 2):

Overall requirement: (1) Diagnosis of ONE of the listed pediatric indications AND (2) Preferred product criteria is met

Approvals provided for specified durations

VTE treatment (pediatric): Venous thromboembolic events, Treatment — Approve for 1 year if patient is ≥ 3 months to < 12 years of age

Examples include DVT, cerebral venous thrombosis, pulmonary embolism, central venous thrombosis

VTE to reduce risk of recurrence (pediatric): Venous thromboembolic events, To Reduce the Risk of Recurrence — Approve for 1 year if patient is ≥ 3 months to < 12 years of age

Examples include DVT, cerebral venous thrombosis, pulmonary embolism, central venous thrombosis

Pradaxa (dabigatran) capsules and Pradaxa oral pellets are not medically necessary when prescribed for any use not explicitly listed as a covered indication in this policy. This includes, but is not limited to, venous thromboembolism (VTE) prophylaxis in an acutely ill medical patient, which is specifically listed as a condition not covered because alternative agents (for example, rivaroxaban/Xarelto) have labeled indications and guideline support for that use.

Policy revisions have modified the set of excluded conditions over time; for example, prophylaxis of VTE in individuals with Factor V Leiden thrombophilia and antiphospholipid syndrome was removed from the list of not-covered conditions in a prior revision. Providers should confirm that the intended use for Pradaxa capsules or oral pellets matches one of the covered indications and age-specific criteria before billing or seeking authorization.

Specific scenarios considered not medically necessary include use of Pradaxa capsules or oral pellets for VTE prophylaxis in an acutely ill medical patient. The policy notes that other agents (for example, Xarelto/rivaroxaban) have labeling and guideline support for prophylaxis in this setting, and therefore dabigatran is excluded for that indication.

Revisions to the policy have altered which conditions are excluded; clinicians should review the current policy language to confirm whether a particular thrombophilia or antiphospholipid-related prophylaxis scenario is covered or excluded, because previous versions removed some exclusions (for example, certain thrombophilia prophylaxis exclusions were removed in a selected revision).

Initial Authorization Durations and Age Limits

inv-12: Initial therapy durations and age limits

Initial authorization durations and age limits are specified by indication.

Atrial fibrillation: Approve for 1 year if patient is ≥ 18 years of age (capsules)

chunk 8

DVT/PE treatment (capsules): Approve for 1 year if patient is ≥ 8 years of age

chunk 8

DVT/PE to reduce risk of recurrence (capsules): Approve for 1 year if patient is ≥ 8 years of age

chunk 8

DVT/PE prophylaxis after hip replacement:

Prior Trials, Step Therapy and Exceptions

Indication / Population	Required prior trial or documentation	Exceptions / Notes
{"text":"Treatment or prevention of other thromboembolic-related conditions (capsules) — patients ≥ 8 years","status":""},{"text":"Failure, contraindication, or intolerance to warfarin, fondaparinux, or a low molecular weight heparin (e.g., enoxaparin, dalteparin) OR patient has been started on dabigatran capsules for acute thromboembolic treatment. Note: prior trial of listed DOACs (apixaban, rivaroxaban, edoxaban) exempts requirement to try warfarin/fondaparinux/LMWH.","status":""},{"text":"Approve for 6 months when criteria met. Examples include superficial vein thrombosis, splanchnic vein thrombosis, hepatic vein thrombosis, or prophylaxis in a high‑risk patient.","status":""}
{"text":"Treatment or prevention of other thromboembolic-related conditions (Pradaxa oral pellets) — pediatric patients ≥ 3 months to < 12 years","status":""},{"text":"Failure, contraindication, or intolerance to ONE of: warfarin, fondaparinux, or a low molecular weight heparin product OR patient has been started on Pradaxa oral pellets for acute thromboembolic treatment.","status":""},{"text":"Approve for 6 months when criteria met. Patients ≥ 3 months to < 12 years; prior use of apixaban, rivaroxaban, or edoxaban exempts the need to try warfarin/fondaparinux/LMWH.","status":""}
{"text":"Pradaxa oral pellets — pediatric patients ≥ 8 and < 12 years with swallowing or intolerance issues","status":""},{"text":"Not strictly a warfarin/LMWH/fondaparinux trial: allowed when patient has intolerance to generic dabigatran capsules OR is unable to swallow capsules AND has failure/contraindication/intolerance to Xarelto (tablets or oral suspension).","status":""},{"text":"Allows pellets as an alternative for swallowing/intolerance when Xarelto trial requirement met; listed under Employer and Individual & Family Plans criteria.","status":""}
{"text":"Pradaxa oral pellets — pediatric patients < 8 years","status":""},{"text":"Failure, contraindication, or intolerance to Xarelto (tablets or oral suspension) is required prior to pellets.","status":""},{"text":"Applies to patients < 8 years per pediatric criteria in the policy; coverage only when criteria met.","status":""}

Drug Products, Strengths and Billing Codes

Drug products and strengths listedNDC

Pradaxa 75 mg	dabigatran capsule strength listed in preferred product table
Pradaxa 110 mg	dabigatran capsule strength listed in preferred product table
Pradaxa 150 mg	dabigatran capsule strength listed in preferred product table
Pradaxa Oral Pellets	dabigatran oral pellets product listed in preferred product table

Prior Authorization, Documentation and Claims Guidance

Prior Authorization

Prior Authorization Required

Prior Authorization Recommended for Dabigatran Capsules (Pradaxa, generic). Prior authorization (PA) is recommended for prescription benefit coverage of dabigatran capsules. Approvals are provided for the duration specified in the policy (months = 30 days). Check plan type: some Employer and Individual & Family plans have specific preferred-product criteria or exceptions for capsules vs oral pellets.

PA applies to dabigatran capsules (Pradaxa and bioequivalent generics).
Approval durations follow the policy criteria (e.g., 60 days, 6 months) and are measured in 30-day months.

Documentation Required

Document Prior Trials / Pediatric Steps

Document trial/failure history and any pediatric-specific steps when requesting coverage. For certain indications, the policy requires documentation of prior trials, contraindications, or intolerance to alternative anticoagulants (e.g., warfarin, fondaparinux, low molecular weight heparin, or specific DOACs as noted). For pediatric patients, age-based criteria and trial requirements differ (see policy sections for age ranges and allowable alternatives).

Dosage, Frequency, Duration and Site of Care Guidance

Documentation Required

Ensure dosage, frequency, duration, and site of care are clinically appropriate

Dosage, frequency, duration of therapy, and site of care must be reasonable, clinically appropriate, and supported by evidence‑based literature; adjust based on severity, alternative treatments, and previous response. When coverage is available and medically necessary, authorizations and site‑of‑care decisions should reflect these principles.

Ensure prescribed dose, frequency, and duration align with policy‑specified approvals (age and indication specific)
Site of care (including home) should be clinically appropriate and supported by evidence

Formulation and Substitutability Notes

Formulation non-substitutability

Key pointNot all dosage forms (capsules vs oral pellets) are approved for the same indications and age groups.

Bioavailability differenceDue to differences in bioavailability, individual products are not substitutable on a mg-per-mg basis.

Clinical implicationFormulation choice must reflect the specific FDA‑approved indication and patient age group rather than assuming milligram equivalence across forms.

Pediatric considerationsPradaxa oral pellets have pediatric approvals distinct from capsules (e.g., pellets for 3 months to <12 years; capsules for 8 to <18 years in some VTE indications).

Policy impactAuthorization and coverage decisions require matching the prescribed formulation to the approved indication and age in the labeling; substitution by mg is not acceptable.

Background and Clinical Context

Dabigatran is a direct thrombin inhibitor available as Pradaxa capsules and Pradaxa oral pellets. It is approved for multiple thromboembolic indications with age- and formulation-specific approvals; recent policy revisions added age restrictions for several indications and clarified pediatric pellet use (including removal of a prior requirement for 5 days of parenteral anticoagulation for pellet-treated VTE).